FDA Warns New Jersey Drugmaker for Repeat Violations

Drug Industry Daily
A A
The FDA issued a warning letter to Nationwide Laboratories over repeated CGMP violations at its Iselin, New Jersey facility, including failing to monitor its contractors.

To View This Article:

Login

Subscribe To Drug Industry Daily